Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.

Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R.

Arch Ophthalmol. 2009 Apr;127(4):381-9. doi: 10.1001/archophthalmol.2009.18.

2.

Short-term topical bevacizumab in the treatment of stable corneal neovascularization.

Cheng SF, Dastjerdi MH, Ferrari G, Okanobo A, Bower KS, Ryan DS, Amparo F, Stevenson W, Hamrah P, Nallasamy N, Dana R.

Am J Ophthalmol. 2012 Dec;154(6):940-948.e1. doi: 10.1016/j.ajo.2012.06.007. Epub 2012 Sep 8.

3.

Topical ranibizumab as a treatment of corneal neovascularization.

Ferrari G, Dastjerdi MH, Okanobo A, Cheng SF, Amparo F, Nallasamy N, Dana R.

Cornea. 2013 Jul;32(7):992-7. doi: 10.1097/ICO.0b013e3182775f8d.

4.

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.

Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C.

Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1375-82. doi: 10.1007/s00417-009-1099-1. Epub 2009 May 5.

PMID:
19415316
5.

The effect of topical bevacizumab on corneal neovascularization.

Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI.

Ophthalmology. 2008 Jun;115(6):e33-8. doi: 10.1016/j.ophtha.2008.02.013. Epub 2008 Apr 24.

PMID:
18439681
6.

Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.

Amparo F, Sadrai Z, Jin Y, Alfonso-Bartolozzi B, Wang H, Shikari H, Ciolino JB, Chodosh J, Jurkunas U, Schaumberg DA, Dana R.

Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):537-44. doi: 10.1167/iovs.12-11032.

7.

Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.

Koenig Y, Bock F, Kruse FE, Stock K, Cursiefen C.

Cornea. 2012 Aug;31(8):887-92. doi: 10.1097/ICO.0b013e31823f8f7a.

PMID:
22362005
8.

Bevacizumab for corneal neovascularization.

Jacobs DS, Lim M, Carrasquillo KG, Rosenthal P.

Ophthalmology. 2009 Mar;116(3):592-3; author reply 593-4. doi: 10.1016/j.ophtha.2008.10.011. No abstract available.

PMID:
19264217
9.

Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.

Dastjerdi MH, Saban DR, Okanobo A, Nallasamy N, Sadrai Z, Chauhan SK, Hajrasouliha AR, Dana R.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2411-7. doi: 10.1167/iovs.09-3745. Epub 2009 Nov 5.

10.

Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.

You IC, Im SK, Lee SH, Yoon KC.

Cornea. 2011 Jan;30(1):30-3. doi: 10.1097/ICO.0b013e3181dc81a0.

PMID:
20861729
11.

The effect of bevacizumab on corneal neovascularization in rabbits.

Kim WJ, Jeong HO, Chung SK.

Korean J Ophthalmol. 2010 Aug;24(4):230-6. doi: 10.3341/kjo.2010.24.4.230. Epub 2010 Aug 3.

12.

Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome.

Uy HS, Chan PS, Ang RE.

Cornea. 2008 Jan;27(1):70-3. doi: 10.1097/ICO.0b013e318158f6ad.

PMID:
18245970
13.

Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.

You IC, Kang IS, Lee SH, Yoon KC.

Acta Ophthalmol. 2009 Sep;87(6):653-8. doi: 10.1111/j.1755-3768.2008.01399.x. Epub 2008 Nov 18.

14.

[Topical inhibition of angiogenesis at the cornea. Safety and efficacy].

Regenfuss B, Bock F, Bachmann B, König Y, Hos D, Parthasarathy A, Cursiefen C.

Ophthalmologe. 2009 May;106(5):399-406. doi: 10.1007/s00347-009-1934-0. Review. German.

PMID:
19396447
15.

Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.

Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A.

Curr Eye Res. 2008 Jan;33(1):23-8. doi: 10.1080/02713680701799101.

PMID:
18214740
16.

Subconjunctival bevacizumab for corneal neovascularization.

Zaki AA, Farid SF.

Acta Ophthalmol. 2010 Dec;88(8):868-71. doi: 10.1111/j.1755-3768.2009.01585.x.

17.

High-dose topical bevacizumab for corneal neovascularization.

Waisbourd M, Levinger E, Varssano D, Moisseiev E, Zayit-Soudri S, Barak A, Loewenstein A, Barequet I.

Pharmacology. 2013;92(5-6):310-4. doi: 10.1159/000356407. Epub 2013 Dec 4.

PMID:
24335191
18.

Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.

Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P; Tübingen Bevacizumab Study Group.

Acta Ophthalmol. 2008 May;86(3):322-8. Epub 2007 Nov 8.

19.

Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.

Ahn YJ, Hwang HB, Chung SK.

Korean J Ophthalmol. 2014 Apr;28(2):177-80. doi: 10.3341/kjo.2014.28.2.177. Epub 2014 Mar 14.

20.

Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Bock F, König Y, Kruse F, Baier M, Cursiefen C.

Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):281-4. Epub 2007 Oct 13.

PMID:
17934753

Supplemental Content

Support Center